YAP pathway inhibition offers a novel mechanism to prevent scar tissue formation by blocking the cellular signals that drive scarring at its source. When fibroblasts—the cells responsible for wound healing—receive signals to activate their YAP pathway, they transform into myofibroblasts, the primary cell type that produces excessive collagen and creates scars.
By inhibiting this pathway, researchers have found a way to essentially “turn off” the scarring command, allowing wounds to heal more like they do in newborns and fetuses, which typically heal without visible scars. Recent preclinical studies, including a landmark experiment in pigs using the YAP inhibitor verteporfin, showed that a single treatment after injury prevented scarring entirely and even restored hair follicles and sweat glands to the healed area. This article explains how YAP pathway inhibition works to prevent and potentially reverse scarring, what evidence supports its effectiveness, and where clinical development stands today.
Table of Contents
- How Does YAP Pathway Inhibition Stop Fibroblasts From Becoming Scar-Producing Cells?
- YAP Inhibition and Collagen Regulation: Why This Changes Scar Development
- What the Animal Models Tell Us About YAP Inhibition and Real-World Scarring
- From Animal Research to Human Potential: Where Are YAP Inhibitors in Clinical Development?
- Beyond Superficial Scars: What YAP Inhibition Can Address That Other Treatments Cannot
- The Mechanotransduction Connection: Why Physical Signals Drive Scarring
- The Future of YAP Inhibitors for Acne and Traumatic Scars
- Conclusion
How Does YAP Pathway Inhibition Stop Fibroblasts From Becoming Scar-Producing Cells?
The YAP and TAZ proteins are molecular switches inside cells that respond to signals from the environment. When tissue is injured and becomes stiffer—as happens during wound healing—fibroblasts detect this physical stiffness through a process called mechanotransduction. This mechanical signal activates YAP/TAZ, which then instructs fibroblasts to differentiate into myofibroblasts. Myofibroblasts are the heavy lifters of scar formation; they produce abnormally large amounts of collagen that cross-links and hardens tissue, creating the visible, rigid appearance of a scar. By inhibiting the YAP pathway, this entire cascade is interrupted before it starts.
The fibroblasts never receive the signal to transform, so they remain in their normal state and continue producing balanced amounts of collagen that integrate naturally into the tissue rather than accumulating into raised or depressed scars. YAP also controls the production of proteins that actively promote fibrosis—including CTGF (connective tissue growth factor) and components of the TGF-β signaling pathway. These are essentially the fuel that keeps scar tissue growing and hardening. When YAP is inhibited, the production of these fibrosis-promoting proteins drops significantly, which means not only is the transformation of fibroblasts prevented, but the biochemical environment that encourages scar formation is actively suppressed. This dual action—blocking cell transformation and reducing pro-scarring molecules—is why YAP inhibition has shown promise against multiple types of scarring, from hypertrophic scars after burns to keloid scars, which are particularly difficult to treat.
YAP Inhibition and Collagen Regulation: Why This Changes Scar Development
collagen is the structural protein that gives tissue its strength and shape. In normal wound healing, fibroblasts produce controlled amounts of collagen, which cross-links and forms scar tissue over several months before gradually remodeling into more normal tissue. In pathological scarring—keloids, hypertrophic scars, and chronic wound scars—this remodeling fails. The fibroblasts keep producing excessive collagen, and the tissue never smooths out or normalizes. YAP/TAZ regulate the genes that encode collagen itself, as well as transglutaminase-2, an enzyme that cross-links collagen molecules and makes scar tissue rigid.
By blocking YAP, you reduce both the amount of collagen being made and the degree to which that collagen is being chemically stabilized into scar tissue. However, there is an important caveat: YAP inhibition must occur during the right window of the healing process to prevent scarring effectively. In the very early stages of healing, fibroblasts still need some activity to close the wound. If YAP is blocked too aggressively or too early, there’s a theoretical risk of impaired wound closure and delayed healing. The preclinical evidence suggests verteporfin works best when given shortly after injury but not immediately—allowing initial hemostasis and wound closure to occur first. In already-formed scars, YAP inhibition appears to reduce fibroblast proliferation and can even induce apoptosis (programmed cell death) in keloid fibroblasts, potentially reversing existing scarring, but the effects are stronger in newer scars than in deeply established ones.
What the Animal Models Tell Us About YAP Inhibition and Real-World Scarring
The most compelling evidence for YAP inhibition comes from a 2023 Science Translational Medicine study in which a single injection of verteporfin (an FDA-approved drug originally used for certain eye conditions) was applied to surgical wounds in pigs. The results were striking: wounds treated with verteporfin healed without visible scars, whereas control wounds scarred normally. Remarkably, the treated areas also regenerated hair follicles and sweat glands that had been destroyed during the initial wound, essentially restoring full skin function. This is not simply scar prevention—it’s regeneration.
The mechanism was shown to involve blocking mechanotransduction, the process by which physical stiffness in tissue signals cells to scar. For keloid scars specifically, laboratory studies on keloid fibroblasts isolated from patients have demonstrated that verteporfin treatment dramatically reduced cell proliferation, inhibited cell migration (the ability of fibroblasts to spread and invade surrounding tissue), induced apoptosis in the scarring cells, and down-regulated collagen production. Corneal scarring—a serious cause of vision loss after eye injury—has also been addressed in rat models, where a single injection of verteporfin combined with hyaluronic acid gel prevented corneal fibrosis and neovascularization (abnormal blood vessel growth). These findings across different tissue types suggest that YAP inhibition is a fundamental anti-scarring mechanism that isn’t specific to one type of scar or one body location.
From Animal Research to Human Potential: Where Are YAP Inhibitors in Clinical Development?
While most evidence for YAP inhibition in scarring comes from preclinical work, clinical research is advancing. VT3989, a TEAD inhibitor that blocks YAP’s downstream signaling, recently received FDA orphan drug designation and fast-track designation for mesothelioma (an asbestos-related cancer with severe fibrosis). This compound is currently in Phase 1/2 clinical trials. Though the initial focus is on cancer and pulmonary fibrosis, the mechanisms that make YAP inhibition effective against fibrosis in the lungs and other organs are the same ones driving skin scarring, so the safety and efficacy data will be highly relevant. Recent 2025 research specifically focused on epithelial cell YAP-TEAD/LOX signaling in lung fibrosis showed that inhibiting this pathway reversed fibrotic cell reprogramming in human lung tissue samples and shifted immune cell balance toward regenerative cells rather than inflammatory cells.
The comparison between YAP inhibitors and current scar treatments is instructive. Silicone gels, pressure garments, and steroid injections address symptoms of existing scars—they can flatten and soften them over time, but they don’t prevent scar formation in the first place. Chemical peels and laser resurfacing remove scar tissue but cause additional injury, which can sometimes paradoxically lead to more scarring in certain individuals. YAP inhibition, by contrast, aims to prevent the fundamental biological process that creates scars in the first place. The tradeoff is that current treatments are available now, while YAP inhibitors are still in clinical development and not yet approved for skin scarring in humans.
Beyond Superficial Scars: What YAP Inhibition Can Address That Other Treatments Cannot
While this article focuses on skin scarring and acne scars, it’s worth understanding that YAP pathway activation drives fibrosis—the pathological accumulation of scar tissue—throughout the body. YAP/TAZ inhibition has been studied in cardiac fibrosis, where it reduces scarring and fibrosis progression in heart tissue, potentially preserving heart function after myocardial infarction. Skeletal muscle fibrosis, which can occur after severe injury or in conditions like muscular dystrophy, also involves TGF-β/SMAD/YAP/TAZ signaling. Pulmonary fibrosis, kidney fibrosis, and liver cirrhosis all involve YAP pathway activation. This suggests that once YAP inhibitors are fully developed and approved, their applications could extend far beyond cosmetic scar improvement to serious organ fibrosis conditions.
However, for acne scars specifically, most current research has been in mice, pigs, and cellular models rather than in human acne scar tissue, which means translation to your skin may require specific clinical trials to determine optimal dosing and timing. A critical limitation to consider is that YAP inhibition is a cellular signal blocker—it prevents cells from receiving and acting on mechanical and biochemical signals. This means its effects depend on treating tissue during the wound-healing or early scarring phase. In deeply established scars that have matured over years, the scar tissue is mechanically stable and the fibroblasts may no longer be actively responding to the signals that YAP controls. Some research suggests YAP inhibitors can induce apoptosis in keloid fibroblasts even in established scars, but the evidence is stronger for prevention than for reversal of old scarring.
The Mechanotransduction Connection: Why Physical Signals Drive Scarring
One of the most important discoveries in scar biology is that scarring isn’t just driven by growth factors in the blood—it’s driven by the physical stiffness of tissue itself. When skin is injured, the wound becomes stiffer as new collagen is laid down. Fibroblasts sense this stiffness and interpret it as a signal to keep producing more collagen, creating a self-amplifying loop. This process is called mechanotransduction, and YAP/TAZ are the key sensors in this pathway.
When researchers blocked mechanotransduction—specifically by inhibiting YAP—the loop was broken, and fibroblasts no longer interpreted tissue stiffness as a scarring signal. The implications are significant: tissue that would normally scar can be “told” to regenerate instead. In the pig wound model, treated animals showed restoration of normal skin architecture with hair and sweat glands, not just scar prevention. This suggests that mechanotransduction inhibition doesn’t just suppress a pathological process—it can redirect healing toward regeneration rather than scarring.
The Future of YAP Inhibitors for Acne and Traumatic Scars
The clinical development of YAP inhibitors is expected to accelerate over the next few years as multiple compounds enter human trials. The success of verteporfin and other inhibitors in animal models, combined with the FDA’s recent fast-track designations for fibrosis-related indications, suggests that regulatory pathways are opening. For acne scars specifically, dermatologists and scar specialists are closely monitoring this research.
If a YAP inhibitor becomes available and is shown to prevent scarring when applied during or shortly after acne inflammation, it could transform acne treatment—potentially making severe acne scars preventable rather than inevitable and difficult to treat after the fact. Currently active clinical trials, including NCT06944249 on ClinicalTrials.gov, are recruiting participants for YAP pathway research, and these studies may provide the first human data on safety and efficacy. The reality is that we are likely several years away from YAP inhibitors being available as a standard acne scar prevention or treatment, but the basic science is compelling and the animal evidence is robust. The coming years will determine whether the promise of verteporfin and similar compounds in pigs translates to effective and safe use in human skin scarring.
Conclusion
YAP pathway inhibition represents a fundamentally different approach to scars than anything currently available. Rather than treating scars after they form, YAP inhibitors aim to prevent scar formation by blocking the cellular transformation and signaling that drives fibroblasts to become scar-producing cells. Animal studies—particularly the pig model showing complete scar prevention and even regeneration of lost skin structures—have demonstrated proof of concept.
The mechanism works by preventing mechanotransduction, reducing pro-fibrosis proteins like CTGF, and in some cases inducing apoptosis in already-scarring fibroblasts. Multiple compounds are in clinical development, and safety data from trials in other fibrosis conditions will help determine the path toward human use in dermatology. If you have active acne or recent traumatic scars and are interested in preventing permanent scarring, stay informed about clinical trial developments and speak with a dermatologist about what emerging therapies might be appropriate for your situation. The next five to ten years are likely to bring significant advances in scar prevention and reversal through YAP pathway inhibition, making what was once inevitable—permanent scarring—potentially avoidable.
